Biotech Startups

Capcyte Biotherapeutics develops surface modification technology for cardiovascular implants to improve hemocompatibility, with applications in therapeutic cell culture and other medical fields.

1 investor

Cape Haven Bio is a venture creation firm focused on translating early-stage academic discoveries into commercially viable biotech companies developing therapeutics. The firm provides strategic planning, lab infrastructure, seed capital, and consulting resources to support the progression from research to investable business.

1 investor

Capital 2B is a venture capital firm that invests in deep-tech and IP-led startups from pre-seed to Series A, writing first cheques of $200k–$3M, often as the first institutional investor. It focuses on companies at the intersection of computation, programmable biology, and advanced materials.

1 investor

Caplin Point Laboratories is a pharmaceutical manufacturer that produces ointments, creams, external applications, and other formulations. Founded in 1990 and publicly listed, the company operates manufacturing facilities in India.

1 investor

Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.

1 investor

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

1 investor

Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells. The company develops fit-for-purpose viral vectors for treating difficult-to-treat diseases, including CNS and neuromuscular disorders.

1 investor

Capsule endoscopy medical device that captures high-resolution images of the digestive system to diagnose gastrointestinal conditions. The swallowable capsule is used to evaluate obscure bleeding, inflammatory diseases, and other GI disorders.

1 investor

CapsulateBio develops ingestible robotic pills for oral delivery of biologic drugs, using platforms that deposit liquid or solid biologics directly into the wall of the small intestine or stomach to achieve injectable-like bioavailability. Spun out of the Langer and Traverso Labs at MIT, the company targets pharmaceutical drug delivery for biologics that have traditionally required injection.

1 investor

Capsule AI builds life-sciences-native AI models and agentic workflows that convert unstructured scientific content—congress coverage, publications, primary research, and figures—into competitive and strategic intelligence for life science teams. Its stack includes a voice agent for HCP/patient engagements, a figure-data extraction model, and a domain-specific embedding model, deployable within an organization's existing cloud infrastructure and data lakes.

1 investor

Cardiac Success develops a cardiac remodeling therapy and the VSling device, which is in first-in-human clinical study. The company works in the medical device field focused on heart treatment.

1 investor

CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.

1 investor

Carina Biotech develops chimeric antigen receptor T cell (CAR-T) therapies and other adoptive cell therapies to treat solid cancers using a patient's immune system. The Australian clinical-stage immunotherapy company creates patient-specific treatments with proprietary platforms designed to improve access to tumors and enhance cell manufacturing.

1 investor

CARMAT develops Aeson, a total artificial heart that replaces both ventricles to treat patients with end-stage biventricular heart failure. The device is commercially available as a bridge to transplant in the European Union and countries recognizing CE marking, and is under an Early Feasibility Study in the United States.

1 investor

Carmeda develops the CARMEDA BioActive Surface, a heparin-based coating technology that it licenses to medical device manufacturers worldwide for use on their approved products. The company operates in the medical device materials and biomaterials industry.

1 investor

1 investor

Carmell Cosmetics sells a line of skincare products built around its Carmell Secretome ingredient, offering crèmes and serums that target dark spots, redness, fine lines, and signs of aging. Its products are sold directly to consumers for everyday skincare routines.

1 investor

Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.

1 investor

CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.

1 investor

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification. The company serves the healthcare and biomanufacturing industries with sol-gel based microcarrier solutions.

1 investor

CARUS Bio develops gene delivery systems and cell-derived biologics for therapeutic applications. The company operates a healthcare division producing skincare and beverage products, while pursuing research in CAR-mRNA technology and therapeutic drug development.

1 investor

Cascade Prodrug is a preclinical-stage pharmaceutical company developing prodrug-based drug candidates, initially targeting wet age-related macular degeneration (wet AMD), with a focus on advancing through IND-enabling studies into clinical trials. The company operates in the biopharmaceutical and drug development sector.

1 investor

Pfizer is a pharmaceutical company that develops medicines across multiple therapeutic areas through extensive clinical research and testing. It serves patients globally with prescription medications and provides patient assistance programs to improve access to healthcare.

1 investor

Case45 is a company referencing the earliest recorded cancer diagnosis, presenting a team working from a London office and a laboratory in Houston. The page provides minimal detail about the company's specific product or services.

1 investor